Literature DB >> 484522

Clinical results of a cross-over treatment with pyridoxine and placebo of the carpal tunnel syndrome.

J Ellis, K Folkers, T Watanabe, M Kaji, S Saji, J W Caldwell, C A Temple, F S Wood.   

Abstract

Clinical evaluation was made of cross-over treatments by pyridoxine and a placebo of patient 22 having the carpal tunnel syndrome. Extraordinary monitoring of the specific activities of the erythrocyte glutamic oxaloacetic transaminase proved a severe vitamin B6 deficiency, which was partially corrected by the Recommended Dietary Allowance of 2 mg, and completely corrected by 100 mg. The severity of the syndrome diminished on the Recommended Dietary Allowances and the patient was asymptomatic at the higher dosage. On placebo, both the vitamin B6 deficiency and syndrome reappeared. Retreatment with 100 mg again corrected both the deficiency and syndrome. Measurements (total n = 19) of flexion of proximal interphalangeal joints of the index fingers by a goniometer, and of pinch by the Preston gauge revealed objective normalization. Scores of 17 symptoms revealed reductions at both the 2- (P less than 0.01) and 100-mg (P less than 0.001) dosages. Conduction through the carpal tunnels had improved by electromyography. These and previous data on a total of 22 patients showed the concomitant presence of a deficiency of vitamin B6 and the carpal tunnel syndrome; a causal relationship is apparent.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 484522     DOI: 10.1093/ajcn/32.10.2040

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  10 in total

Review 1.  What can family physicians offer patients with carpal tunnel syndrome other than surgery? A systematic review of nonsurgical management.

Authors:  Felicity Goodyear-Smith; Bruce Arroll
Journal:  Ann Fam Med       Date:  2004 May-Jun       Impact factor: 5.166

Review 2.  Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control.

Authors:  J R Miranda-Massari; M J Gonzalez; F J Jimenez; M Z Allende-Vigo; J Duconge
Journal:  Curr Clin Pharmacol       Date:  2011-11

Review 3.  Vitamin therapy in the absence of obvious deficiency. What is the evidence?

Authors:  L Ovesen
Journal:  Drugs       Date:  1984-02       Impact factor: 9.546

4.  Carpal tunnel syndrome and vitamin B6.

Authors:  F J Laso Guzmán; J M González-Buitrago; F de Arriba; F Mateos; J C Moyano; T López-Alburquerque
Journal:  Klin Wochenschr       Date:  1989-01-04

5.  Response of vitamin B-6 deficiency and the carpal tunnel syndrome to pyridoxine.

Authors:  J M Ellis; K Folkers; M Levy; S Shizukuishi; J Lewandowski; S Nishii; H A Schubert; R Ulrich
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

6.  Bilateral carpal tunnel syndrome associated with interleukin 2 therapy.

Authors:  S D Heys; K L Mills; O Eremin
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

7.  The carpal tunnel syndrome in hypertensive patients treated with beta-blockers.

Authors:  M K Emara; A M Saadah
Journal:  Postgrad Med J       Date:  1988-03       Impact factor: 2.401

8.  Enzymology of the response of the carpal tunnel syndrome to riboflavin and to combined riboflavin and pyridoxine.

Authors:  K Folkers; A Wolaniuk; S Vadhanavikit
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

9.  Randomized clinical trial of surgery versus conservative therapy for carpal tunnel syndrome [ISRCTN84286481].

Authors:  Brook I Martin; Linda M Levenson; William Hollingworth; Michel Kliot; Patrick J Heagerty; Judith A Turner; Jeffrey G Jarvik
Journal:  BMC Musculoskelet Disord       Date:  2005-01-18       Impact factor: 2.362

Review 10.  New candidates for treatment and management of carpal tunnel syndrome based on the Persian Canon of Medicine.

Authors:  Mohammad Setayesh; Arman Zargaran; Amir Reza Sadeghifar; Mehdi Salehi; Hossein Rezaeizadeh
Journal:  Integr Med Res       Date:  2018-02-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.